Jun 29, 2021
Dr. Jennifer Gudeman was hired for the newly formed role of Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. We talk about the clinical development of their lead investigational product FT218 to treat the rare disease narcolepsy. Optimized the drug delivery release of sodium oxybate with their proprietary controlled-release technology allows for a single bedtime dose.
While the FDA nearly 20 years ago approved sodium oxybate to treat cataplexy and excessive daytime sleepiness, the drug was an immediate-release medication requiring a middle-of-the-night dose. After a successful Phase 3 clinical trial, Avadel's ongoing open-label study, RESTORE, is providing evidence that points to more restorative sleep across a broad audience.
@AvadelPharma $AVDL #narcolepsy #rarediseases #cataplexy #sleepdisorders #sleep #EDS #neurotwitter